Activated Protein C in Ischemia-Reperfusion Injury After Experimental Lung Transplantation

Journal of Heart and Lung Transplantation

Volumn 28, Issue 11, 2009, Pages 1180-1184

  Hirayama, Shin ^a   Cypel, Marcelo ^a   Sato, Masaaki ^a   Anraku, Masaki ^a   Liaw, Patricia C ^b   Liu, Mingyao ^a   Waddell, Thomas K ^a   Keshavjee, Shaf ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; THROMBIN ANTITHROMBIN COMPLEX; TUMOR NECROSIS FACTOR ALPHA;

AIRWAY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLD ISCHEMIA; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FIBRIN DEPOSITION; ISCHEMIA; LUNG ALVEOLUS; LUNG FUNCTION; LUNG INJURY; LUNG ISCHEMIA; LUNG PARENCHYMA; LUNG TRANSPLANTATION; MALE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OXYGENATION; PRIORITY JOURNAL; PULMONARY ARTERY; RAT; REPERFUSION INJURY;

ANIMALS; ANTITHROMBIN III; CHEMOKINE CXCL2; CITRATES; CYTOKINES; GRAFT SURVIVAL; INFLAMMATION; INTERLEUKIN-1; INTERLEUKIN-6; LUNG; LUNG TRANSPLANTATION; MALE; ORGAN PRESERVATION; PEPTIDE HYDROLASES; PROTEIN C; RATS; RATS, INBRED LEW; REPERFUSION; REPERFUSION INJURY; TISSUE PRESERVATION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70350077254     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2009.06.026     Document Type: Article

References (28)

1. Christie J.D., Edwards L.B., Aurora P., et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report-2008. J Heart Lung Transplant 27 (2008) 957-969
2. Fischer S., Bohn D., Rycus P., et al. Extracorporeal membrane oxygenation for primary graft dysfunction after lung transplantation: analysis of the Extracorporeal Life Support Organization (ELSO) registry. J Heart Lung Transplant 26 (2007) 472-477
3. Shargall Y., Guenther G., Ahya V.N., Ardehali A., Singhal A., and Keshavjee S. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part VI: treatment. J Heart Lung Transplant 24 (2005) 1489-1500
4. Howard T.K., Klintmalm G.B., Cofer J.B., Husberg B.S., Goldstein R.M., and Gonwa T.A. The influence of preservation injury on rejection in the hepatic transplant recipient. Transplantation 49 (1990) 103-107
5. Shackleton C.R., Ettinger S.L., McLoughlin M.G., Scudamore C.H., Miller R.R., and Keown P.A. Effect of recovery from ischemic injury on class I and class II MHC antigen expression. Transplantation 49 (1990) 641-644
6. Daud S.A., Yusen R.D., Meyers B.F., et al. Impact of immediate primary lung allograft dysfunction on bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 175 (2007) 507-513
7. Mosnier L.O., Zlokovic B.V., and Griffin J.H. The cytoprotective protein C pathway. Blood 109 (2007) 3161-3172
8. Idell S. Coagulation, fibrinolysis, and fibrin deposition in acute lung injury. Crit Care Med 31 (2003) S213-S220
9. Taylor Jr. F.B., Chang A., Esmon C.T., D'Angelo A., Vigano-D'Angelo S., and Blick K.E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 79 (1987) 918-925
10. Murakami K., Okajima K., Uchiba M., et al. Activated protein C prevents LPS-induced pulmonary vascular injury by inhibiting cytokine production. Am J Physiol 272 (1997) L197-L202
11. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 344 (2001) 699-709
12. Christie J.D., Robinson N., Ware L.B., et al. Association of protein C and type 1 plasminogen activator inhibitor with primary graft dysfunction. Am J Respir Crit Care Med 175 (2007) 69-74
13. Abraham E., Laterre P.F., Garg R., et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 353 (2005) 1332-1341
14. Hirayama S., Shiraishi T., Shirakusa T., Higuchi T., and Miller E.J. Prevention of neutrophil migration ameliorates rat lung allograft rejection. Mol Med 12 (2006) 208-213
15. de Perrot M., Quadri S.M., Imai Y., and Keshavjee S. Independent ventilation of the graft and native lungs in vivo after rat lung transplantation. Ann Thorac Surg 79 (2005) 2169-2171
16. Liaw P.C., Esmon C.T., Kahnamoui K., et al. Patients with severe sepsis vary markedly in their ability to generate activated protein C. Blood 104 (2004) 3958-3964
17. de Perrot M., Young K., Imai Y., et al. Recipient T cells mediate reperfusion injury after lung transplantation in the rat. J Immunol 171 (2003) 4995-5002
18. Murao Y., Loomis W., Wolf P., Hoyt D.B., and Junger W.G. Effect of dose of hypertonic saline on its potential to prevent lung tissue damage in a mouse model of hemorrhagic shock. Shock 20 (2003) 29-34
19. de Perrot M., Liu M., Waddell T.K., and Keshavjee S. Ischemia-reperfusion-induced lung injury. Am J Respir Crit Care Med 167 (2003) 490-511
20. Shimizu S., Gabazza E.C., Taguchi O., et al. Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 167 (2003) 1416-1426
21. Yasui H., Gabazza E.C., Tamaki S., et al. Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse. Am J Respir Crit Care Med 163 (2001) 1660-1668
22. Yuda H., Adachi Y., Taguchi O., et al. Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood 103 (2004) 2196-2204
23. Slofstra S.H., Groot A.P., Maris N.A., Reitsma P.H., Cate H.T., and Spek C.A. Inhalation of activated protein C inhibits endotoxin-induced pulmonary inflammation in mice independent of neutrophil recruitment. Br J Pharmacol 149 (2006) 740-746
24. Kotanidou A., Loutrari H., Papadomichelakis E., et al. Inhaled activated protein C attenuates lung injury induced by aerosolized endotoxin in mice. Vascul Pharmacol 45 (2006) 134-140
25. Esmon C.T. Crosstalk between inflammation and thrombosis. Maturitas 47 (2004) 305-314
26. Vincent J.L., Bernard G.R., Beale R., et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 33 (2005) 2266-2277
27. Dahlback B., and Villoutreix B.O. Regulation of blood coagulation by the protein C anticoagulant pathway: novel insights into structure-function relationships and molecular recognition. Arterioscler Thromb Vasc Biol 25 (2005) 1311-1320
28. Nick J.A., Coldren C.D., Geraci M.W., et al. Recombinant human activated protein C reduces human endotoxin-induced pulmonary inflammation via inhibition of neutrophil chemotaxis. Blood 104 (2004) 3878-3885